The Role of Fibrinolytic System in Health and Disease
| dc.contributor.editor | Kwaan, Hau C. | |
| dc.date.accessioned | 2022-07-06T11:55:13Z | |
| dc.date.available | 2022-07-06T11:55:13Z | |
| dc.date.issued | 2022 | |
| dc.identifier | ONIX_20220706_9783036546193_136 | |
| dc.identifier.uri | https://directory.doabooks.org/handle/20.500.12854/87541 | |
| dc.description.abstract | This is a review of the topic of fibrinolysis contributed by authors who are specialized in the clinical and basic studies of this topic. These include: the endothelial receptor of tissue plasminogen activator, by Dr. Katherine Hajjar; regulation of S100 by pml-rar-alpha oncoprotein, by Dr. O’Connell; receptor of urokinase type plasminogen activator, by Dr. M. Ploug et al.; tissue plasminogen activator induction in purjinjen neuron, by Dr. Seeds; fibrinolysis from the blood to the brain, by Dr. Robert Metcalf; tissue plasminogen activator induces the opening of the blood–brain barrier, by Dr. M. Yepes; fibrinolysis shutdown in trauma: a historical review and clinical application, by Drs. Hunter Moore and Ernest Moore; fibrinolysis in immunity, by Drs. K. Kolev and Robert Medcalf; the role of plasminogen activator inhibitor 1, by Drs. M. Erin, A.E. Boe, and E.A. Klyachko; and finally, persistent fibrinolysis shutdown is associated with increased mortality in severely injured trauma patients, by J.P. Meizoso. | |
| dc.language | English | |
| dc.subject.classification | thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general | en_US |
| dc.subject.classification | thema EDItEUR::P Mathematics and Science::PS Biology, life sciences | en_US |
| dc.subject.other | COVID-19 | |
| dc.subject.other | fibrinolysis | |
| dc.subject.other | renin-aldosterone-angiotensin-system (RAAS) | |
| dc.subject.other | plasminogen activator inhibitor 1 (PAI-1) | |
| dc.subject.other | urokinase plasminogen activator | |
| dc.subject.other | urokinase plasminogen activator receptor | |
| dc.subject.other | plasminogen activator inhibitor-1 | |
| dc.subject.other | acute lung injury and repair and pleural injury and pleural organization | |
| dc.subject.other | PAI-1 | |
| dc.subject.other | cardiovascular disease | |
| dc.subject.other | cancer | |
| dc.subject.other | inflammation | |
| dc.subject.other | fibrosis | |
| dc.subject.other | aging | |
| dc.subject.other | obstructive sleep apnoea | |
| dc.subject.other | OSA | |
| dc.subject.other | coagulation | |
| dc.subject.other | platelets | |
| dc.subject.other | brown adipose tissue | |
| dc.subject.other | obesity | |
| dc.subject.other | plasminogen activation | |
| dc.subject.other | immune response | |
| dc.subject.other | thrombin activatable fibrinolysis inhibitor | |
| dc.subject.other | TAFI | |
| dc.subject.other | proCPU | |
| dc.subject.other | proCPB | |
| dc.subject.other | proCPR | |
| dc.subject.other | carboxypeptidase | |
| dc.subject.other | uPA | |
| dc.subject.other | uPAR | |
| dc.subject.other | PA system | |
| dc.subject.other | tissue-type plasminogen activator (tPA) | |
| dc.subject.other | urokinase-type plasminogen activator (uPA) | |
| dc.subject.other | neurodegeneration | |
| dc.subject.other | thrombin | |
| dc.subject.other | shear | |
| dc.subject.other | clot retraction | |
| dc.subject.other | Factor XIII | |
| dc.subject.other | clot stability | |
| dc.subject.other | NETs | |
| dc.subject.other | plasmin | |
| dc.subject.other | plasminogen activator | |
| dc.subject.other | PAI-2 | |
| dc.subject.other | antiplasmin | |
| dc.title | The Role of Fibrinolytic System in Health and Disease | |
| dc.type | book | |
| oapen.identifier.doi | 10.3390/books978-3-0365-4620-9 | |
| oapen.relation.isPublishedBy | 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 | |
| oapen.relation.isbn | 9783036546193 | |
| oapen.relation.isbn | 9783036546209 | |
| oapen.pages | 170 | |
| oapen.place.publication | Basel |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||

